PTGS2 and lung carcinoma: Although COX-2 alone may not serve as a stand-alone prognostic marker for lung cancer, several upstream and downstream effectors within the COX-2 pathway have demonstrated potential as biomarkers for predicting cancer prognosis and metastatic potential [31].